Atossa Therapeutics, Inc. ( (ATOS) ) has released its Q3 earnings. Here is a breakdown of the information Atossa Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Atossa Therapeutics, Inc. is a biotechnology company focused on developing innovative medicines for significant unmet medical needs in oncology, particularly breast cancer and other breast conditions. The company recently released its earnings report for the third quarter of 2025, highlighting a net loss of $8.7 million, which is an increase from the $7.2 million loss reported in the same period last year. The company’s operating expenses rose significantly due to increased research and development costs, which amounted to $5.4 million for the quarter, reflecting its continued investment in clinical trials and drug development. Despite the financial losses, Atossa Therapeutics maintains a cash reserve of $51.8 million, which the management believes is sufficient to fund operations for at least one year. Looking ahead, the company plans to continue its focus on developing its lead program, (Z)-endoxifen, for metastatic breast cancer, while exploring additional funding opportunities to support its long-term strategic goals.